Regulatory Question Marks Shed Uncertainty on the US Molecular Imaging and Diagnostic Radiopharmaceutical Industry

Published: 28 Aug 2017

The past few months have placed a cloud of uncertainty over the future of healthcare in the United States. At the time of writing this article, Senate Republicans have failed to secure the necessary votes to pass the Better Care Reconciliation Act (BCRA). An assessment of the two failed acts, the American Healthcare Act and the BCRA is indicative of the fact that future iterations are expected to be along the same lines in terms of policy with minor changes and concessions. Rollback of Medicaid expansion will continue to remain a key priority and the phased replacement of Medicaid expansion with state-wise lump sum payments will result in millions of Americans losing their health insurance. This coupled with continued Medicare cuts, and greater leeway given to insurers in deciding premiums will further contribute to a significant reduction in the insured population over a period of time. With the delay of Bundled Payments till 2018—which include bundles for acute myocardial infarction and coronary artery bypass graft coupled with an unlikely, but possible shift away from value-based models in favor of older fee for service models—participants across the entire healthcare value chain have more questions than answers.

Sign in to read the rest of this article

Not signed up? Register now Forgot your password?

Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..